Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided AI assessment’s pregnancy/fetal toxicity statements and the instruction to discontinue upon pregnancy detection are explicitly supported by the supplied FDA label excerpts for Benicar, Tribenzor, and Benicar HCT.
Category Scores
Accurate Statements
Fetal harm/fetal toxicity from RAS-directed drugs (olmesartan-containing products) and potential fetal/neonatal morbidity and death are supported by the label.
Benicar (olmesartan medoxomil) 5.1 and 8.1; Tribenzor 5.1 and 8.1; Benicar HCT 5.1 and 8.1 excerpts provided.
When pregnancy is detected, discontinue as soon as possible is supported by the label for Benicar/Tribenzor/Benicar HCT.
Benicar 5.1 and 8.1; Tribenzor 5.1 and 8.1; Benicar HCT 5.1 and 8.1 excerpts provided.
The claim elements were evaluated as 'supported' based on explicit label fetal toxicity and pregnancy risk summaries for the specified products.
Directly consistent with the supplied excerpts for Benicar, Tribenzor, and Benicar HCT.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The evaluated statements concern pregnancy-related fetal toxicity and the label-consistent discontinuation instruction; no conflicting or speculative claims were included in the provided assessment.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement